SOHO 2018 | Predictors for TFR in CML: response duration, secondary treatment & frontline TKI choice
Timothy Hughes
• 12 Sep 2018
Speaking from the 2018 Society of Hematologic Oncology (SOHO) Annual Meeting in Houston, TX, Timothy Hughes, MD, FRACP, FRCPA, of the Royal Adelaide Hospital, Adelaide, Australia, discusses predictors of treatment-free remission (TFR) in chronic myeloid leukemia (CML). Prof. Hughes highlights what the EURO-SKI trial (NCT01596114) demonstrated about the importance of the duration of a deep molecular response, and what ENESTop (NCT01698905) and other trials have shown about the impact of second-line treatment. He also explores what the ENESTFreedom study (NCT01784068) indicates about starting frontline treatment with a second generation TKI.
